نتائج البحث

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (CRISTALLO)

• Source: A Prospective, Open-Label, Multicenter Randomized Phase III Study to Compare The Efficacy and Safety of A Combined Regimen of Venetoclax and Obinutuzumab Versus

تفاصيل العنوان

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

• Source: A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR)

تفاصيل العنوان

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab

• Authors : Jurgen Barth, Professor Mathias Rummel

• Source: Prospective Randomised Multicenter Study for Therapy Optimization of Recurrent, Progressive Low Grade Non-Hodgkin Lymphomas and Mantle Cell Lymphomas58. Rummel MJ et al. Bendamustine Plus

تفاصيل العنوان

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

• Authors : National Cancer Institute (NCI); Mehrdad Abedi, MD, Principal Investigator

• Source: A Phase I Study to Evaluate the Safety of Escalating Doses of Lymphodepleting Conditioning Chemotherapy Prior to CD19 Chimeric Antigen Receptor T Cells in Subjects With Relapsed/Refractory Diffuse

تفاصيل العنوان

A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan

• Authors : National Cancer Institute (NCI)

• Source: A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Non-Hodgkin Lymphoma Using Zevalin, Fludarabine and Melphalan

تفاصيل العنوان

Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

• Authors : Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; SWOG Cancer Research Network

• Source: A Genetic Risk-Stratified, Randomized Phase II Study of Four Fludarabine/Antibody Combinations for Patients With Symptomatic, Previously Untreated Chronic Lymphocytic

تفاصيل العنوان

Inferior Outcomes of Fludarabine–Cyclophosphamide–Rituximab Chemotherapy in Korean Chronic Lymphocytic Leukemia Patients with Concurrent Thrombocytopenia and Anemia

• Authors : Tong-Yoon Kim; Gi-June Min; Young-Woo Jeon

Subjects: chronic lymphocytic leukemia; bicytopenia B-cell; chemotherapy

• Source: Biomedicines, Vol 13, Iss 1, p 194 (2025)

تفاصيل العنوان

Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide (FCR)

• Authors : Celgene Corporation

• Source: Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With

تفاصيل العنوان

Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment.

• Authors : Xu, Xiaoli¹ (AUTHOR); Zhao, Ying¹ (AUTHOR); Ye, Haiyan¹ (AUTHOR)

• Source: Computational & Mathematical Methods in Medicine. 10/3/2022, p1-21. 21p.

تفاصيل العنوان

Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population.

• Authors : Molica, Stefano¹ (AUTHOR) ; Shanafelt, Tait D.² (AUTHOR) ; Allsup, David^1,3 (AUTHOR)

• Source: Cancers. Mar2024, Vol. 16 Issue 6, p1085. 10p.

تفاصيل العنوان